Reconciliations of these measures to GAAP measures are available on our earnings release and supplemental presentation on our website. Our forward-looking metrics such as annual contract value continued to improve to 1.6%, making a 30 basis point sequential improvement driven by 2% ACV growth across academia and government. In Life Sciences and Health, our renewal rate of 93%, an important indicator, was up 100 basis points year-over-year. Our free cash flow generation continues to support our balanced capital allocation, including $150 million of opportunistic share repurchases year-to-date as well as $100 million of debt paid down.
On slide seven, our VCP is driving improved focus, growth, and innovation across the business. We expect this R&D investment to result in higher organic growth and improved renewal rates in the future. Our sales execution has improved support, stronger customer engagement, and revenue retention, helping us achieve our organic growth outlook through the first nine months of 2025. We continue to see strong renewal patterns with 90% of global A&G subscription for the full year successfully renewed through October 27.
Moving to the Intellectual Property segment, for the first nine months, the patent and trademark maintenance services recurring revenue was flat compared to the same period last year. We are encouraged by this as it represents 3% improvement in the organic growth rate relative to the full year of 2024. While these results show improvement, we are committed to returning the segment to sustainable growth. Moving to the Life Sciences and Health segment, I am personally excited it has returned to 2% ACV growth this year.